Latest Breaking News On - Hedge funds weigh in on biocryst pharmaceuticals - Page 1 : vimarsana.com

FY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $13.29 Consensus Target Price from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of "Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 30,130,000 shares, a decline of 31.8% from the October 15th total of 44,190,000 shares. Based on an average daily volume of 2,770,000 shares, […]

BioCryst Pharmaceuticals (NASDAQ:BCRX) Raised to "Outperform" at Royal Bank of Canada

Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a sector perform rating to an outperform rating in a research report sent to investors on Monday morning, Marketbeat.com reports. Royal Bank of Canada currently has $10.00 price target on the biotechnology company’s stock, up from their prior price target of […]